182 related articles for article (PubMed ID: 33863896)
1. Phenotypic discordance between primary and metastatic breast cancer in the large-scale real-life multicenter French ESME cohort.
Grinda T; Joyon N; Lusque A; Lefèvre S; Arnould L; Penault-Llorca F; Macgrogan G; Treilleux I; Vincent-Salomon A; Haudebourg J; Maran-Gonzalez A; Charafe-Jauffret E; Courtinard C; Franchet C; Verriele V; Brain E; Tas P; Blanc-Fournier C; Leroux A; Loussouarn D; Berghian A; Brabencova E; Ghnassia JP; Scoazec JY; Delaloge S; Filleron T; Lacroix-Triki M
NPJ Breast Cancer; 2021 Apr; 7(1):41. PubMed ID: 33863896
[TBL] [Abstract][Full Text] [Related]
2. Time trends of overall survival among metastatic breast cancer patients in the real-life ESME cohort.
Gobbini E; Ezzalfani M; Dieras V; Bachelot T; Brain E; Debled M; Jacot W; Mouret-Reynier MA; Goncalves A; Dalenc F; Patsouris A; Ferrero JM; Levy C; Lorgis V; Vanlemmens L; Lefeuvre-Plesse C; Mathoulin-Pelissier S; Petit T; Uwer L; Jouannaud C; Leheurteur M; Lacroix-Triki M; Cleaud AL; Robain M; Courtinard C; Cailliot C; Perol D; Delaloge S
Eur J Cancer; 2018 Jun; 96():17-24. PubMed ID: 29660596
[TBL] [Abstract][Full Text] [Related]
3. The Prognostic Impact of Hormonal Receptor and HER-2 Expression Discordance in Metastatic Breast Cancer Patients.
Yang Z; Li N; Li X; Lei L; Wang X
Onco Targets Ther; 2020; 13():853-863. PubMed ID: 32099389
[TBL] [Abstract][Full Text] [Related]
4. CinéBreast-factors influencing the time to first metastatic recurrence in breast cancer: Analysis of real-life data from the French ESME MBC database.
Gougis P; Carton M; Tchokothe C; Campone M; Dalenc F; Mailliez A; Levy C; Jacot W; Debled M; Leheurteur M; Bachelot T; Hennequin A; Perrin C; Gonçalves A; Uwer L; Eymard JC; Petit T; Mouret-Reynier MA; Chamorey E; Simon G; Saghatchian M; Cailliot C; Le Tourneau C
Breast; 2020 Feb; 49():17-24. PubMed ID: 31675683
[TBL] [Abstract][Full Text] [Related]
5. Contemporary outcomes of metastatic breast cancer among 22,000 women from the multicentre ESME cohort 2008-2016.
Deluche E; Antoine A; Bachelot T; Lardy-Cleaud A; Dieras V; Brain E; Debled M; Jacot W; Mouret-Reynier MA; Goncalves A; Dalenc F; Patsouris A; Ferrero JM; Levy C; Lorgis V; Vanlemmens L; Lefeuvre-Plesse C; Mathoulin-Pelissier S; Petit T; Uwer L; Jouannaud C; Leheurteur M; Lacroix-Triki M; Courtinard C; Perol D; Robain M; Delaloge S
Eur J Cancer; 2020 Apr; 129():60-70. PubMed ID: 32135312
[TBL] [Abstract][Full Text] [Related]
6. Study of Biomarker Discordance between Primary and Recurrent Sites and its Clinical Implications in Metastatic Breast Cancer : A Single Institutional Study from India.
Shanthala S; Amirtham U; Gopal C; N SM; Jacob L; Babu G
South Asian J Cancer; 2024 Apr; 13(2):90-98. PubMed ID: 38919661
[TBL] [Abstract][Full Text] [Related]
7. Incidence and outcome of brain and/or leptomeningeal metastases in HER2-low metastatic breast cancer in the French ESME cohort.
Epaillard N; Lusque A; Jacot W; Mailliez A; Bachelot T; Arnedos M; Le Du F; Brain E; Ferrero JM; Massard V; Desmoulins I; Mouret-Reynier MA; Levy C; Gonçalves A; Leheurteur M; Petit T; Filleron T; Bosquet L; Pistilli B; Frenel JS
ESMO Open; 2024 May; 9(5):103447. PubMed ID: 38703431
[TBL] [Abstract][Full Text] [Related]
8. Evolution of overall survival and receipt of new therapies by subtype among 20 446 metastatic breast cancer patients in the 2008-2017 ESME cohort.
Grinda T; Antoine A; Jacot W; Blaye C; Cottu PH; Diéras V; Dalenc F; Gonçalves A; Debled M; Patsouris A; Mouret-Reynier MA; Mailliez A; Clatot F; Levy C; Ferrero JM; Desmoulins I; Uwer L; Petit T; Jouannaud C; Lacroix-Triki M; Deluche E; Robain M; Courtinard C; Bachelot T; Brain E; Pérol D; Delaloge S
ESMO Open; 2021 Jun; 6(3):100114. PubMed ID: 33895695
[TBL] [Abstract][Full Text] [Related]
9. Assessment of the efficacy of successive endocrine therapies in hormone receptor-positive and HER2-negative metastatic breast cancer: a real-life multicentre national study.
Le Saux O; Lardy-Cleaud A; Frank S; Debled M; Cottu PH; Pistilli B; Vanlemmens L; Leheurteur M; Lévy C; Laborde L; Uwer L; D'hondt V; Berchery D; Lorgis V; Ferrero JM; Perrocheau G; Courtinard C; Mouret-Reynier MA; Velten M; Breton M; Parent D; Chabaud S; Robain M; Bachelot T
Eur J Cancer; 2019 Sep; 118():131-141. PubMed ID: 31330488
[TBL] [Abstract][Full Text] [Related]
10. Discordances in estrogen receptor status, progesterone receptor status, and HER2 status between primary breast cancer and metastasis.
Curtit E; Nerich V; Mansi L; Chaigneau L; Cals L; Villanueva C; Bazan F; Montcuquet P; Meneveau N; Perrin S; Algros MP; Pivot X
Oncologist; 2013 Jun; 18(6):667-74. PubMed ID: 23723333
[TBL] [Abstract][Full Text] [Related]
11. Discordance in receptor status between primary and metastatic breast cancer and overall survival: A single-center analysis.
Mellouli M; Graja S; Kridis WB; Ayed HB; Makni S; Triki M; Charfi S; Khanfir A; Boudawara TS; Kallel R
Ann Diagn Pathol; 2022 Dec; 61():152044. PubMed ID: 36099874
[TBL] [Abstract][Full Text] [Related]
12. Real-life prognosis of 5041 bone-only metastatic breast cancer patients in the multicenter national observational ESME program.
Bertho M; Fraisse J; Patsouris A; Cottu P; Arnedos M; Pérol D; Jaffré A; Goncalves A; Lebitasy MP; D'Hondt V; Dalenc F; Ferrero JM; Levy C; Dabakuyo S; Rouzier R; Penault-Llorca F; Uwer L; Eymard JC; Breton M; Chevrot M; Thureau S; Petit T; Simon G; Frénel JS
Ther Adv Med Oncol; 2021; 13():1758835920987657. PubMed ID: 33613700
[TBL] [Abstract][Full Text] [Related]
13. The ongoing French metastatic breast cancer (MBC) cohort: the example-based methodology of the Epidemiological Strategy and Medical Economics (ESME).
Pérol D; Robain M; Arveux P; Mathoulin-Pélissier S; Chamorey E; Asselain B; Berchery D; Gourgou S; Breton M; Delaine-Clisant S; Mons M; Diéras V; Carton M; Guizard AV; Laborde L; Laurent C; Loeb A; Mouret-Reynier MA; Parent D; Perrocheau G; Campion L; Velten M; Cailliot C; Ezzalfani M; Simon G
BMJ Open; 2019 Feb; 9(2):e023568. PubMed ID: 30796119
[TBL] [Abstract][Full Text] [Related]
14. A Prospective Multi-Institutional Observational Study on ER, PR, HER2/NEU, and Ki-67 Expression and Discordance Pattern in Primary and Metastatic and Recurrent Carcinoma Breast and Its Therapeutic Implications and Prognostic Outcome.
Satishkumar M; Ramesh M; Sanjive JG
Indian J Surg Oncol; 2023 Mar; 14(1):72-80. PubMed ID: 36891419
[TBL] [Abstract][Full Text] [Related]
15. Estrogen, progesterone, and human epidermal growth factor receptor 2 discordance between primary and metastatic breast cancer.
Walter V; Fischer C; Deutsch TM; Ersing C; Nees J; Schütz F; Fremd C; Grischke EM; Sinn P; Brucker SY; Schneeweiss A; Hartkopf AD; Wallwiener M
Breast Cancer Res Treat; 2020 Aug; 183(1):137-144. PubMed ID: 32613540
[TBL] [Abstract][Full Text] [Related]
16. Estrogen/progesterone receptor and HER2 discordance between primary tumor and brain metastases in breast cancer and its effect on treatment and survival.
Sperduto PW; Mesko S; Li J; Cagney D; Aizer A; Lin NU; Nesbit E; Kruser TJ; Chan J; Braunstein S; Lee J; Kirkpatrick JP; Breen W; Brown PD; Shi D; Shih HA; Soliman H; Sahgal A; Shanley R; Sperduto W; Lou E; Everett A; Boggs DH; Masucci L; Roberge D; Remick J; Plichta K; Buatti JM; Jain S; Gaspar LE; Wu CC; Wang TJC; Bryant J; Chuong M; Yu J; Chiang V; Nakano T; Aoyama H; Mehta MP
Neuro Oncol; 2020 Sep; 22(9):1359-1367. PubMed ID: 32034917
[TBL] [Abstract][Full Text] [Related]
17. Characteristics and survival in bone metastatic breast cancer patients with different hormone receptor status: A population-based cohort study.
Jiang X; Chen G; Sun L; Liu C; Zhang Y; Liu M; Liu C
Front Oncol; 2022; 12():977226. PubMed ID: 36091103
[TBL] [Abstract][Full Text] [Related]
18. Age related influence of triple receptor status on metastatic breast cancer post relapse survival.
Todorovic-Rakovic N; Neskovic-Konstantinovic Z
J BUON; 2013; 18(4):851-8. PubMed ID: 24344008
[TBL] [Abstract][Full Text] [Related]
19. Endocrine therapy or chemotherapy as first-line therapy in hormone receptor-positive HER2-negative metastatic breast cancer patients.
Jacquet E; Lardy-Cléaud A; Pistilli B; Franck S; Cottu P; Delaloge S; Debled M; Vanlemmens L; Leheurteur M; Guizard AV; Laborde L; Uwer L; Jacot W; Berchery D; Desmoulins I; Ferrero JM; Perrocheau G; Courtinard C; Brain E; Chabaud S; Robain M; Bachelot T
Eur J Cancer; 2018 May; 95():93-101. PubMed ID: 29655061
[TBL] [Abstract][Full Text] [Related]
20. Association between progression-free survival and overall survival in women receiving first-line treatment for metastatic breast cancer: evidence from the ESME real-world database.
Courtinard C; Gourgou S; Jacot W; Carton M; Guérin O; Vacher L; Bertaut A; Le Deley MC; Pérol D; Marino P; Levy C; Uwer L; Perrocheau G; Schiappa R; Bachelot F; Parent D; Breton M; Petit T; Filleron T; Loeb A; Pélissier SM; Robain M; Delaloge S; Bellera C
BMC Med; 2023 Mar; 21(1):87. PubMed ID: 36882736
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
